Benefits
Mood support
One randomized, placebo-controlled trial enrolled 124 Iranian women aged 18-35 who scored 12-23 on the Edinburgh Postnatal Depression Scale. Over 8 weeks scores fell in both arms - from 15.83 to 1.72 with the blend and from 15.45 to 5.85 with placebo - leaving an adjusted difference of 4.35 points (95% CI 2.77-5.94) in favour of the blend. Much of the improvement occurred in the placebo group as well, the two groups differed at baseline in age and education, and the trial has not been repeated by anyone. This is a single small study in women receiving clinical follow-up, not a reason to use a supplement for a mood disorder.
Inflammation — not measured in people
The single human trial of this blend measured depression scores only. No inflammatory marker - CRP, IL-6, TNF-alpha or any other - was measured at any timepoint, so nothing is known about what this preparation does to inflammation in people. Curcumin's effects on inflammatory signaling come from laboratory work and from trials of standardized curcumin extracts, which are far more concentrated preparations than turmeric root powder.
Antioxidant activity — laboratory evidence
Curcuminoids and gingerols scavenge free radicals in laboratory assays. No antioxidant or oxidative-stress marker was measured in the one human trial of this blend, so for this product the antioxidant story remains laboratory evidence rather than a demonstrated effect in people.
Mechanism of action
NF-kB inhibition
In cell and animal models curcumin downregulates NF-kB, a regulator of inflammatory gene expression. This is a proposed mechanism from preclinical work; it has not been confirmed in anyone taking this blend, and the doses used in laboratory models bear no relation to what a 320 mg turmeric powder capsule delivers.
Neuro-supportive signaling
Animal and cell studies report that curcumin influences monoamine and BDNF-related signaling and reduces neuroinflammation. These are proposed explanations drawn from preclinical work and from studies of concentrated curcumin extracts; none of these pathways was measured in the human trial of this blend.
Clinical trials
Randomized, placebo-controlled trial with participants and the researcher dispensing capsules both blinded. n=124 (62 blend / 62 placebo), 8 weeks, single health clinic in Ahvaz, Iran; registered IRCT20210822052254N1. Capsules were compounded at Ahvaz Jundishapur University's school of pharmacology: turmeric root powder 320 mg, ginger 150 mg, black pepper 4 mg, one daily; placebo was a matched 600 mg capsule of Avicel, starch, gelatin and magnesium stearate. The study was funded by Ahvaz Jundishapur University of Medical Sciences, and the authors declared no commercial or financial relationships. (Nikpour et al. 2024, Frontiers in Psychiatry)
124 Iranian women aged 18-35, within 6 months of a low-risk term delivery, scoring 12-23 on the Edinburgh Postnatal Depression Scale. Women with severe depression or suicidal thoughts were excluded and referred to a psychiatrist.
EPDS scores fell in both arms: 15.83 to 3.48 to 1.72 with the blend, and 15.45 to 7.22 to 5.85 with placebo, at baseline, week 4 and week 8. The adjusted between-group difference was 3.97 points at week 4 (95% CI 2.09-5.84) and 4.35 points at week 8 (95% CI 2.77-5.94), both p<0.0001. The placebo arm improved by about 9.6 points on its own, so most of the change over 8 weeks was not attributable to the capsule. The groups differed significantly at baseline in participant age (26.12 vs 23.95 years, p=0.006) and in participant and husband education (p=0.001 and p=0.014). No participant in either arm reported a side effect. The authors state this was the first use of the blend for this purpose and that an effective dose is not established.